SAI PARENTERALS LIMITED
Latest filings
Next results: Sun, 1 Nov · Financial Results- Board to review September 2026 quarter and half-year results · Results
- RTA confirms no demat or remat requests in Q2 FY27 · Compliance
- Sai Parenterals acquires 60 percent in Prathyak Labs for Rs 15 crore · Compliance
Snapshot
What the business is, and whether it's a good one at a fair price.
Operates as a global pharmaceutical formulations platform combining injectable manufacturing in India with an IP-led OTC business in Australia and New Zealand, the latter added through the November 2025 acquisition of a 74.6% stake in Noumed Pharmaceuticals. Revenue flows through three channels: a CDMO export business contributing over 50% of consolidated FY26 revenue under long-term supply contracts into regulated markets; domestic branded formulations in India; and Noumed's OTC and private-label products sold into Australian pharmacy networks. A USD 11 million, 10-year exclusive anti-TB supply contract to the Philippines and an AUD 202 million (~INR 1,300 crore), 7.5-year exclusive OTC supply agreement with Australia's leading pharmacy network are the largest disclosed orders. The company is investing INR 440 crore across India EU-GMP upgrades, an R&D centre and an Adelaide manufacturing facility, all expected to commission by Q4 FY27. Materials are the dominant input cost at 62.5% of revenue, and FY27 revenue is guided at INR 750 crore with a 17% EBITDA margin.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Nothing stands out in the filed numbers.Concerns
Charts
How has the market priced it — with filings on the timeline?
SAIPARENT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from SAI PARENTERALS LIMITED's filed financials and exchange disclosures
What does SAI PARENTERALS LIMITED do?
SAI PARENTERALS LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol SAIPARENT.
Does SAI PARENTERALS LIMITED pay a dividend?
Not in the latest reported year — SAI PARENTERALS LIMITED's dividend payout for FY26 was nil.
Is SAI PARENTERALS LIMITED debt-free?
On a net basis, yes. It reported borrowings of ₹319 Cr on its 31 Mar 2026 balance sheet, but holds ₹97 Cr more cash than debt.
How much does the SAI PARENTERALS LIMITED share price move in a day?
On a typical session SAI PARENTERALS LIMITED moves 1.23% — that is the median absolute close-to-close move across its last 138 trading days. MarketPing measures each filing's price reaction against it.
When are SAI PARENTERALS LIMITED's next results?
Financial Results on Sun, 1 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track SAI PARENTERALS LIMITED's announcements?
Every NSE and BSE filing by SAI PARENTERALS LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.